KLRS logo

KALARIS THERAPEUTICS INC

KLRSNASDAQ
πŸ† #4433 by market capEarnings Mar 16US Equity
$1.28β–Ό $0.07 (βˆ’5.19%)
Market closed Β· at close
πŸ””
Track KLRS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.2%
7dβ–Ό 21.5%
14dβ–Ό 47.5%
30dβ–Ό 32.6%
ytdβ–Ό 84.8%
1yβ–Ό 81.6%
🏦Market Cap
$30M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.26 – $1.37
52-Week Range
$1.33 – $11.88
Volume (shares)
37,990
Avg Volume (shares)
β€”
Shares Outstanding
23.8M
Next Earnings
2027-03-16

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-2.09
Dividend Yield
β€”
Dilution (1yr)
+356.2%
KLRS logo

KALARIS THERAPEUTICS INC

KLRS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$46Mβ–Ό βˆ’16.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$39Mβ–Ό βˆ’43.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
22.9Mβ–² +356.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$97Mβ–Ό βˆ’$22M YoY
StockOtter Β· stockotter.space

About KALARIS THERAPEUTICS INC

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates